Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
IRVINE, Calif., Oct. 05, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq:ICPT). Investors who purchased or otherwise acquired shares between May 31, 2016, and September 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the November 27, 2017 lead plaintiff motion deadline.
If you purchased Intercept shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. When this news was announced, shares of Intercept fell in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
